IGF1R and neoplasm: Altogether, the combined treatment resulted in a decrease in the mean tumor mass compared to mice treated with either the anti-PD-1 or the IGF1R inhibitor, and delayed ascites development compared to the control and the anti-PD-1, and improved survival in the combined treatment compared to anti-PD-1 treatment alone.